April 16, 2020
In Vivo vs. In Vitro Therapeutic Antibody Discovery
April Webinar
- Speaker
Lei Chen, Ph.D.
Senior Director of Antibody Discovery of Biocytogen
- Title
RenMab™ Mouse: a leading platform for fully human antibody generation
- Time
- April 16, 2020 11:00 am
- Track
Lead and Candidate Selection for Therapeutic Proteins
- Abstract
- in vivo antibody discovery using transgenic/humanized mice is of rising importance for the antibody community as it offers a multitude of benefits over in vitro methods (such as phage display of immune libraries) and humanization of murine antibodies. Biocytogen’s antibody discovery expert, Dr. Lei Chen will speak on current antibody discovery platforms, focusing in on a fully human antibody mouse (RenMab™ Mouse), as well as on how to expedite the screening of antibody candidates, from early discovery to in vivo efficacy investigations. Key points to cover by Dr. Lei Chen in the webinar: - Juxtaposing in vivo and in vitro platforms for antibody discovery - Benefits of in vivo method for antibody screening - Features of the fully human antibodies generated by RenMab™ Mouse Biocytogen’s Project Integrum, known as project “RenMab + target KO,” provides the ultimate platform to find antibodies for difficult targets such as GPCR Preview of other upcoming humanized platforms for bispecific (RenLite™ for common light chain) and single-domain antibodies (RenNano™ for heavy chain only) An accelerated antibody discovery workflow that leverages RenMab™ Mouse and target-humanized animal models